Scarica l'app Stockscreener
1.24
2.48%
0.03
Dopo l'orario di chiusura:
1.24
Precedente Chiudi:
$1.21
Aprire:
$1.25
Volume 24 ore:
1.63M
Relative Volume:
0.44
Capitalizzazione di mercato:
$275.13M
Reddito:
$95,000
Utile/perdita netta:
$-327.27M
Rapporto P/E:
-0.5849
EPS:
-2.12
Flusso di cassa netto:
$-239.25M
1 W Prestazione:
+3.33%
1M Prestazione:
+0.00%
6M Prestazione:
-26.19%
1 anno Prestazione:
-51.47%
Intervallo 1D:
$1.21
$1.28
Intervallo di 1 settimana:
$1.205
$1.31
Portata 52W:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Nome
Allogene Therapeutics Inc
Settore
Industria
Telefono
(650) 457-2700
Indirizzo
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Confronta ALLO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.24 | 268.48M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-05-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | Ripresa | Oppenheimer | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-01-05 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-01-05 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | Iniziato | Citigroup | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-06 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-08-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-03 | Iniziato | Robert W. Baird | Neutral |
| 2022-02-28 | Reiterato | B. Riley Securities | Buy |
| 2021-10-20 | Iniziato | Cowen | Outperform |
| 2021-10-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-10-08 | Downgrade | Stifel | Buy → Hold |
| 2021-09-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | Ripresa | Jefferies | Buy |
| 2021-05-20 | Aggiornamento | Truist | Hold → Buy |
| 2021-05-14 | Iniziato | B. Riley Securities | Buy |
| 2021-01-26 | Aggiornamento | Stifel | Hold → Buy |
| 2020-12-10 | Ripresa | H.C. Wainwright | Buy |
| 2020-11-24 | Iniziato | BofA Securities | Buy |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-06-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-19 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2020-05-15 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-14 | Downgrade | SunTrust | Buy → Hold |
| 2020-04-13 | Iniziato | SunTrust | Buy |
| 2020-03-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-24 | Iniziato | Berenberg | Hold |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-11-04 | Iniziato | Canaccord Genuity | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-06-05 | Iniziato | ROTH Capital | Neutral |
| 2019-05-31 | Iniziato | Guggenheim | Neutral |
| 2019-05-23 | Iniziato | Stifel | Hold |
| 2019-03-29 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie
Using AI based signals to follow Allogene Therapeutics Inc.Trend Reversal & Smart Allocation Stock Tips - newser.com
Price action breakdown for Allogene Therapeutics Inc.July 2025 Levels & Accurate Intraday Trading Signals - newser.com
Risk adjusted return profile for Allogene Therapeutics Inc. analyzedPortfolio Growth Summary & AI Driven Stock Reports - newser.com
Applying Elliott Wave Theory to Allogene Therapeutics Inc.Quarterly Portfolio Report & Consistent Profit Trading Strategies - newser.com
Published on: 2025-11-02 02:58:33 - newser.com
What candlestick patterns are forming on Allogene Therapeutics Inc.Chart Signals & Community Trade Idea Sharing Platform - newser.com
Will breakout in Allogene Therapeutics Inc. lead to full recoveryJuly 2025 Market Mood & Precise Buy Zone Tips - newser.com
How sentiment analysis helps forecast Allogene Therapeutics Inc.2025 Market WrapUp & Weekly High Return Stock Forecasts - newser.com
Detecting support and resistance levels for Allogene Therapeutics Inc.July 2025 WrapUp & AI Forecast for Swing Trade Picks - newser.com
Allogene Therapeutics (ALLO) to Release Quarterly Earnings on Thursday - MarketBeat
Will Allogene Therapeutics Inc. stock remain a Wall Street favoriteDollar Strength & High Return Trade Opportunity Guides - newser.com
Chart based analysis of Allogene Therapeutics Inc. trendsPortfolio Update Report & Verified Technical Trade Signals - newser.com
Will Allogene Therapeutics Inc. stock deliver better than expected guidanceJuly 2025 Pullbacks & Pattern Based Trade Signal System - newser.com
Allogene Therapeutics (NASDAQ: ALLO) sets Q3 2025 results; webcast at 2 p.m. PT - Stock Titan
Will Allogene Therapeutics Inc. stock beat EPS estimatesEarnings Risk Report & Free Growth Oriented Trading Recommendations - Fundação Cultural do Pará
Using portfolio simulators with Allogene Therapeutics Inc. includedQuarterly Earnings Report & Safe Entry Point Alerts - newser.com
Allogene Therapeutics targets lupus with RESOLUTION trial launch - Traders Union
Will Allogene Therapeutics Inc. stock deliver strong dividend growthGap Down & Short-Term Trading Alerts - Fundação Cultural do Pará
Pharma News: Will Allogene Therapeutics Inc. stock deliver better than expected guidance2025 Winners & Losers & AI Powered Buy and Sell Recommendations - Fundação Cultural do Pará
Allogene Therapeutics Inc Azioni (ALLO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):